7 million to general and administrative expenses. The ongoing company authorized the grant of 4,500,000 limited shares, equivalent to 450,000 ADSs, to directors, officers and certain workers on November 7, 2011. The restricted shares vest at the ultimate end of a two-year period. Amortization of acquired intangible possessions for 2Q FY2011 was RMB47.2 million that was all allocated to cost of revenues. Related StoriesNew findings reveal association between colorectal malignancy and melanoma medication treatmentNew antenna-like gadget makes breast cancer medical procedures much easier for surgeonsViralytics enters into medical trial collaboration agreement with MSDAs of September 30, 2011, the business’s cash and money equivalents were RMB1,316.8 million .AMAGINE-2 Research Style AMAGINE-2 is a Stage III study that assessed the security and efficacy of brodalumab provided at two doses every fourteen days via subcutaneous injection compared with Stelara and placebo in sufferers with moderate-to-severe plaque psoriasis. The analysis also assessed the basic safety and efficacy of four maintenance regimens of brodalumab. The primary endpoint comparing 210 mg of brodalumab as well as a pre-specified weight-based evaluation group with Stelara was the proportion of individuals attaining total clearance of skin condition, as measured by PASI 100 at week 12.